De Witte Jan's Form 4 filing
Resmed Inc (RMD) · filed Nov 13, 2025
- Accession no.
- 0000943819-25-000115
- Filed
- Nov 13, 2025
- Trade date
- Nov 11, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $121.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| De Witte JanCIK 0001776929 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 11, 2025 | ReMed Common Stock | SSaleDisposed | −487 | $250.25 | −$121,871.75 | 5,319 | Direct | |
| Nov 11, 2025 | ReMed Common Stock | FTax withholdingDisposed | −76.45 | $250.10 | −$19,120.15 | 5,242 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.